JAHA:先天性心脏病妇女妊娠的产妇和新生儿结局分析

2021-04-06 MedSci原创 MedSci原创

当代患有CHD的妇女妊娠通常对产妇和新生儿都有较成功的结局。然而,随着产妇CHD严重程度的增加,许多发病率和新生儿死亡率的风险也随之增加。

随着先天性心脏病(CHD)治疗的进步,更多患有CHD的妇女能从童年存活到生育年龄。

近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,该研究旨在评估当代妊娠的CHD女性产妇和新生儿结局。

研究人员对2007年1月至2019年6月期间发表的同行评审文献进行了荟萃分析。如果研究报告了产妇或胎儿的死亡率,并提供了CHD病变的数据,则纳入进行分析。研究人员采用随机效应回归模型和综合Meta分析(v3)进行了Meta分析。CHD病变分为轻度、中度和重度,以便跨研究收集数据。

研究人员检索到的2200篇文献中,有32篇符合本研究的纳入标准。总的来说,轻、中、重度病变的新生儿死亡率分别为1%、3.1%和3.5%。在任何群体中,孕产妇死亡人数都太少,无法汇集数据。CHD妇女的产妇和新生儿发病率随着病变的严重程度而增加。具体来说,随着孕产妇CHD严重程度的增加,孕产妇心律失常、心力衰竭、剖宫产、早产和小于胎龄儿的发生率均显著增加。

由此可见,当代患有CHD的妇女妊娠通常对产妇和新生儿都有较成功的结局。然而,随着产妇CHD严重程度的增加,许多发病率和新生儿死亡率的风险也随之增加。这些结果可能有助于计划妊娠的CHD妇女孕前咨询,特别是伴有严重病变的CHD妇女

原始出处:

Isabel Hardee.et al.Maternal and Neonatal Outcomes of Pregnancies in Women With Congenital Heart Disease: A Meta‐Analysis.J AM HEART ASSOC.2021.https://www.ahajournals.org/doi/full/10.1161/JAHA.120.017834

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1268485, encodeId=265f126848572, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 08 13:41:05 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369542, encodeId=f76e1369542ce, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 08 13:41:05 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955017, encodeId=919b95501e4f, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b72f5379188, createdName=ms8000001383156651, createdTime=Wed Apr 07 19:36:20 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954348, encodeId=d5919543489e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Tue Apr 06 23:54:49 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
    2021-04-08 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1268485, encodeId=265f126848572, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 08 13:41:05 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369542, encodeId=f76e1369542ce, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 08 13:41:05 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955017, encodeId=919b95501e4f, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b72f5379188, createdName=ms8000001383156651, createdTime=Wed Apr 07 19:36:20 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954348, encodeId=d5919543489e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Tue Apr 06 23:54:49 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1268485, encodeId=265f126848572, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 08 13:41:05 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369542, encodeId=f76e1369542ce, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 08 13:41:05 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955017, encodeId=919b95501e4f, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b72f5379188, createdName=ms8000001383156651, createdTime=Wed Apr 07 19:36:20 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954348, encodeId=d5919543489e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Tue Apr 06 23:54:49 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
    2021-04-07 ms8000001383156651

    学习啦

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1268485, encodeId=265f126848572, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Thu Apr 08 13:41:05 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369542, encodeId=f76e1369542ce, content=<a href='/topic/show?id=bc9f28589d0' target=_blank style='color:#2F92EE;'>#先天性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28589, encryptionId=bc9f28589d0, topicName=先天性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Thu Apr 08 13:41:05 CST 2021, time=2021-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=955017, encodeId=919b95501e4f, content=学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b72f5379188, createdName=ms8000001383156651, createdTime=Wed Apr 07 19:36:20 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=954348, encodeId=d5919543489e, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmhead/Q3auHgzwzM6P57Bs8gOPaY1cQP9lIia0lmZOEXraGaoicqNToIslXDKw/0, createdBy=7a041951742, createdName=衣带渐宽, createdTime=Tue Apr 06 23:54:49 CST 2021, time=2021-04-06, status=1, ipAttribution=)]
    2021-04-06 衣带渐宽

    学习

    0

相关资讯

任明明教授:“左手拿刀,右手导管”——先心病外科治疗的未来发展之路

近年来,先天性心脏病外科治疗技术发展迅速,诊疗理念及治疗策略不断进步。小切口外科手术和导管介入治疗逐渐成为这一领域的热点。

张玉顺教授:从介入器械研发应用谈我国先天性心脏病治疗进展

创伤小、风险低、并发症少、住院周期短……,近年来发展成熟的介入治疗为精准治疗提供了更多可能,也为患者带来了更多获益。

Circulation:全国不同医院先天性心脏手术预后对比

中国新血管疾病现有患者达到3.3亿人。手术治疗是部分心脏病的主要治疗方式,不同医院的手术水平残次不齐。本研究旨在评估不同医院间的病例组合校正的手术死亡率、主要并发症和术后住院时间。

Heart:C反应蛋白在先天性心脏病成人中的预后价值

Hs-CRP对死亡或HF的预后价值增加,超过NT-proBNP和hs-肌钙蛋白T。Hs-CRP在HF或死亡发生前升高,这些结果支持炎症在ACHD患者临床恶化中的作用。

JAHA:先天性心脏病患者接受心脏再同步化治疗的长期预后

先天性心脏病患者接受CRT与约50%的患者可接受的生存期和长期反应相关。CRT继续顺利进行的可能性不大。

张伟华:先天性心脏病的镶嵌治疗

随着先天性心脏病(先心病)治疗手段的迅速发展,微创手术、腔内介入等手段都对临床治疗起了很大的推动作用,但主要应用于简单先心病。对于复杂先心病,近年来提出了介入治疗与外科手术治疗联合应用。